BI-836858 

BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

BI-836858 (10 μg/mL; 30 min) mediates specific ADCC activity against primary AML blasts^[1].
BI-836858 (2 μg/mL; 4 h) mediates NK cell-dependent ADCC activity against CD33-positive HL60 cells^[2].
BI-836858 (2 μg/mL; 48 h) blocks the CD33-mediated inhibitory signaling pathway in MDS bone marrow cells and reduces the expression of IL-10 and TGFβ^[2].
BI-836858 (2 μg/mL) specifically blocks CD33 (S100A9)-mediated ROS production in U937 cells, healthy PBMCs, and primary MDS BM HSPCs^[2].
BI-836858 (2 μg/mL; 14 days) restores the hematopoietic colony-forming capacity in ex vivo cultures of primary MDS bone marrow specimens^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

933  [NCBI]

P20273

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.86 kDa

Liquid

Colorless to light yellow

N/A

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Immobilized huCD33-his can bind BI-836858. The EC₅₀ for this effect is 9.98 ng/mL.

• [1]. Gopalakrishnan B, et al. Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget. 2018;9(11):9706-9713. Published 2018 Jan 3.  [Content Brief]

  [2]. Eksioglu EA, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172-2180.  [Content Brief]